» Articles » PMID: 30189184

Role of Hippocampal 5-HT1A Receptors in the Antidepressant-like Phenotype of Mice Expressing RGS-insensitive Gαi2 Protein

Overview
Specialties Neurology
Pharmacology
Date 2018 Sep 7
PMID 30189184
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

A single base mutation in the Gα protein (G184S) renders this Gα subunit insensitive to the negative modulatory effects of Regulator of G-protein Signaling (RGS) proteins. Mice expressing this RGS insensitive (RGSi) variant of Gα (RGSi Gα) display a spontaneous antidepressant-like phenotype that is reversible by treatment with the 5-HT1A receptor (5-HT1AR) antagonist WAY100635. Here we test the hypothesis that increased activity of 5-HT1ARs in the hippocampus of RGSi Gα knock-in mice is responsible for the expression of the observed antidepressant-like behavior. We administered the 5-HT1AR antagonist WAY100635 or the agonist 8-OH-DPAT via bilateral intra-hippocampal infusion cannulae and evaluated antidepressant-like behavior using the tail suspension test (TST). WAY100635 reversed the antidepressant-like phenotype of the RGSi Gα knock-in mice and 8-OH-DPAT produced an antidepressant-like response in wild type mice that was blocked by systemic WAY100635. Furthermore, intra-hippocampal infusion of the RGS19/4 inhibitor CCG-203769 produced an antidepressant-like effect in female mice. Ex-vivo slice recording confirmed the 5-HT1AR-mediated decrease in hippocampal CA1 pyramidal neuron excitability was enhanced in the RGSi Gα knock-in mice. There was no change in hippocampal 5-HT1AR expression as measured by ligand binding but there was a compensatory reduction in Gαi proteins. The findings demonstrate that RGS protein control of hippocampal 5-HT1AR signaling is necessary and sufficient to account for the antidepressant-like phenotype in the RGSi Gα knock-in mice and that RGS proteins highly expressed in the hippocampus should be investigated as targets for novel antidepressant therapies.

Citing Articles

The Role of G-proteins and G-protein Regulating Proteins in Depressive Disorders.

Senese N, Rasenick M, Traynor J Front Pharmacol. 2018; 9:1289.

PMID: 30483131 PMC: 6244039. DOI: 10.3389/fphar.2018.01289.

References
1.
Hjorth S, Bengtsson H, Kullberg A, Carlzon D, Peilot H, Auerbach S . Serotonin autoreceptor function and antidepressant drug action. J Psychopharmacol. 2000; 14(2):177-85. DOI: 10.1177/026988110001400208. View

2.
Rabiner E, Gunn R, Castro M, Sargent P, Cowen P, Koepp M . beta-blocker binding to human 5-HT(1A) receptors in vivo and in vitro: implications for antidepressant therapy. Neuropsychopharmacology. 2000; 23(3):285-93. DOI: 10.1016/S0893-133X(00)00109-3. View

3.
Dong M, Chase D, Patikoglou G, Koelle M . Multiple RGS proteins alter neural G protein signaling to allow C. elegans to rapidly change behavior when fed. Genes Dev. 2000; 14(16):2003-14. PMC: 316861. View

4.
Cho H, Kozasa T, Takekoshi K, de Gunzburg J, Kehrl J . RGS14, a GTPase-activating protein for Gialpha, attenuates Gialpha- and G13alpha-mediated signaling pathways. Mol Pharmacol. 2000; 58(3):569-76. DOI: 10.1124/mol.58.3.569. View

5.
Malberg J, Eisch A, Nestler E, Duman R . Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci. 2000; 20(24):9104-10. PMC: 6773038. View